Carlsmed® Announces Financial Results for Q2 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 28 2025
0mins
Should l Buy CARL?
Source: Newsfilter
Q2 Financial Performance: Carlsmed, Inc. reported a revenue of $12.1 million for Q2 2025, marking a 99% year-over-year growth from $6.1 million in Q2 2024, driven by increased adoption of their AI-enabled aprevo® technology platform.
Operating Expenses and Net Loss: Operating expenses rose to $15.4 million in Q2 2025 compared to $10.9 million in the same quarter last year, resulting in a net loss of $6.8 million, slightly higher than the previous year's loss of $6.3 million.
Future Outlook: The company anticipates full-year revenue for 2025 to be between $45.5 million and $47.5 million, reflecting a growth of 67% to 75% over 2024, as they prepare to launch personalized cervical spine surgery in 2026.
Cash Position: As of June 30, 2025, Carlsmed had cash and cash equivalents of $33.5 million, bolstered by $93.5 million raised from its initial public offering in July 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CARL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CARL
Wall Street analysts forecast CARL stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.760
Low
18.00
Averages
20.50
High
24.00
Current: 10.760
Low
18.00
Averages
20.50
High
24.00
About CARL
Carlsmed, Inc. is a commercial-stage medical technology company providing AI-enabled personalized spine surgery solutions. Its aprevo technology platform offers solutions for the entire surgical workflow, including pre-operative AI-enabled, surgical planning; intra-operative advanced visualization to support precision placement of aprevo interbody implants, and post-operative data collection and insights intended to improve the digital surgical planning process. Its pre-operative planning software utilizes standard-of-care diagnostic imaging and AI-enabled algorithms to develop personalized digital surgical plans and to design aprevo interbody implants for each patient's pathology and vertebral bone topography. Additionally, the aprevo technology platform supports the collection of real-world, post-operative data to inform its digital surgical planning process. Its platform is commercially available in the United States and is indicated for use in lumbar interbody fusion procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Carlsmed to Report Q4 and Full Year 2025 Results on February 25
- Earnings Report Schedule: Carlsmed will release its Q4 and full year 2025 financial results after market close on February 25, 2026, providing investors with the latest insights into the company's operational performance.
- Conference Call Details: Management will host a conference call and webcast at 1:30 PM Pacific Time, with participants encouraged to dial in 5 to 10 minutes early to ensure they receive timely updates on company developments.
- Replay Availability: A replay of the webcast will be available shortly after the call concludes, allowing investors who could not attend live to review the meeting content, thereby enhancing information transparency.
- Company Mission: Carlsmed is committed to improving healthcare outcomes and reducing costs for spine surgery through AI-enabled personalized solutions, showcasing its innovative potential and competitive edge in the medical technology sector.
See More
Heineken Plans 7% Workforce Layoffs to Boost Efficiency
- Layoff Plan: Heineken plans to cut 5,000 to 6,000 jobs over the next two years, representing about 7% of its 87,000 workforce, aiming to enhance productivity in response to a 2.4% decline in beer sales last year.
- Profit Growth Target: Despite the drop in total beer volumes, Heineken's adjusted operating profit rose by 4.4%, with the company forecasting operating profit growth of 2% to 6% for 2026, demonstrating resilience in a challenging market environment.
- Digital Transformation: The layoffs are partly attributed to the push for AI and digitization, with around 3,000 roles expected to move to business services, aiming for annual savings of €400 to €500 million, further advancing its EverGreen 2030 strategy.
- Market Reaction: Heineken's shares rose 3.4% in the latest trading session, and the stock is up nearly 7% year-to-date, reflecting market confidence in its strategic adjustments and future growth potential.
See More
Carlsmed Completes First Lumbar Spine Surgery with Aprevo System
- Surgical Milestone: Carlsmed successfully completed its first posterior lumbar spine surgery using the aprevo® Bi-lateral Posterior System at the University of Colorado Hospital, reinforcing the company's leadership in personalized spine solutions.
- Technological Advantage: The system integrates AI-enabled software and clinical intelligence, allowing surgeons to plan with greater precision, thereby improving patient outcomes and reducing costly revision surgeries.
- Market Outlook: Carlsmed anticipates a full commercial launch of the system later this year, aiming to provide personalized procedural options to patients, surgeons, and hospital systems, thereby expanding its market share.
- Surgeon Feedback: Dr. CJ Kleck emphasized that the aprevo® technology is crucial across all surgical stages, enabling tailored treatment based on each patient's anatomy and pathology, which enhances confidence in achieving alignment goals.
See More
Danish Brewer's Earnings Decline Amid Increased Soft Drink Reliance
- Earnings Decline: The Danish brewer reported a decline in earnings primarily due to a softening consumer appetite for beer, which has negatively impacted overall sales and the company's financial health.
- Increased Soft Drink Reliance: In response to declining beer sales, the company is increasingly relying on its soft drink offerings, a shift that may alleviate some pressure in the short term but could affect brand image and market positioning in the long run.
- Changing Market Demand: As consumer preferences shift towards healthier beverage options, the beer industry faces significant challenges, forcing the company to reassess its product portfolio to align with new market trends.
- Need for Strategic Adjustment: Given the earnings decline, the Danish brewer must develop new strategies to enhance its competitiveness in the soft drink market while also seeking effective ways to revive beer sales.
See More
Novo Nordisk Warns of Sales Decline Amid Price Pressures
- Sales Warning: Novo Nordisk released its earnings report early, projecting a decline in sales and profit growth this year primarily due to lower prices in the U.S. and the loss of exclusivity for its weight loss drugs Wegovy and Ozempic in China, Brazil, and Canada, which may dampen market confidence.
- Stock Reaction: Following the warning, Novo Nordisk's share price tumbled significantly, reflecting investor concerns about future performance, which could impact the company's competitiveness and investor confidence in global markets.
- Market Impact: European stocks are expected to open flat to higher, with the FTSE and DAX slightly up, and the CAC 40 rising by 0.24%, indicating a cautiously optimistic market sentiment ahead of upcoming earnings reports, despite overall sentiment being affected by a short-lived sell-off in cryptocurrencies and precious metals.
- Earnings Focus: On Wednesday, several companies including Novo Nordisk, Banco Santander, and GSK are set to report earnings, with the market closely monitoring these reports for their implications on overall economic and industry trends, especially amid increasing economic uncertainty.
See More
Trump Reaches Greenland Framework Agreement, European Stocks Rise
- Market Rebound: Following Trump's announcement of a framework agreement with NATO Secretary General, European stocks are expected to open higher, with the UK's FTSE up 0.8%, Germany's DAX up 1.3%, France's CAC 40 up 1.2%, and Italy's FTSE MIB up 1.5%, reflecting positive market sentiment amid easing trade tensions.
- Framework Agreement Details: During the World Economic Forum in Davos, Trump indicated that the framework would involve U.S.-European collaboration on a proposed Golden Dome missile defense system and access to mineral resources in Greenland, although he acknowledged that specific details are still to be clarified.
- Trade Agreement Uncertainty: Despite the framework agreement, European lawmakers have suspended the approval of last year's EU-U.S. trade deal, introducing uncertainty into future trade relations and potentially impacting market confidence.
- Global Economic Impact: Trump's address and the agreement may influence global economic trends, particularly regarding trade policies and international cooperation, likely prompting further discussions among business leaders and political figures at the World Economic Forum.
See More
Carlsmed to Report Q4 and Full Year 2025 Results on February 25
- Earnings Report Schedule: Carlsmed will release its Q4 and full year 2025 financial results after market close on February 25, 2026, providing investors with the latest insights into the company's operational performance.
- Conference Call Details: Management will host a conference call and webcast at 1:30 PM Pacific Time, with participants encouraged to dial in 5 to 10 minutes early to ensure they receive timely updates on company developments.
- Replay Availability: A replay of the webcast will be available shortly after the call concludes, allowing investors who could not attend live to review the meeting content, thereby enhancing information transparency.
- Company Mission: Carlsmed is committed to improving healthcare outcomes and reducing costs for spine surgery through AI-enabled personalized solutions, showcasing its innovative potential and competitive edge in the medical technology sector.
See More
Heineken Plans 7% Workforce Layoffs to Boost Efficiency
- Layoff Plan: Heineken plans to cut 5,000 to 6,000 jobs over the next two years, representing about 7% of its 87,000 workforce, aiming to enhance productivity in response to a 2.4% decline in beer sales last year.
- Profit Growth Target: Despite the drop in total beer volumes, Heineken's adjusted operating profit rose by 4.4%, with the company forecasting operating profit growth of 2% to 6% for 2026, demonstrating resilience in a challenging market environment.
- Digital Transformation: The layoffs are partly attributed to the push for AI and digitization, with around 3,000 roles expected to move to business services, aiming for annual savings of €400 to €500 million, further advancing its EverGreen 2030 strategy.
- Market Reaction: Heineken's shares rose 3.4% in the latest trading session, and the stock is up nearly 7% year-to-date, reflecting market confidence in its strategic adjustments and future growth potential.
See More
Carlsmed Completes First Lumbar Spine Surgery with Aprevo System
- Surgical Milestone: Carlsmed successfully completed its first posterior lumbar spine surgery using the aprevo® Bi-lateral Posterior System at the University of Colorado Hospital, reinforcing the company's leadership in personalized spine solutions.
- Technological Advantage: The system integrates AI-enabled software and clinical intelligence, allowing surgeons to plan with greater precision, thereby improving patient outcomes and reducing costly revision surgeries.
- Market Outlook: Carlsmed anticipates a full commercial launch of the system later this year, aiming to provide personalized procedural options to patients, surgeons, and hospital systems, thereby expanding its market share.
- Surgeon Feedback: Dr. CJ Kleck emphasized that the aprevo® technology is crucial across all surgical stages, enabling tailored treatment based on each patient's anatomy and pathology, which enhances confidence in achieving alignment goals.
See More
Danish Brewer's Earnings Decline Amid Increased Soft Drink Reliance
- Earnings Decline: The Danish brewer reported a decline in earnings primarily due to a softening consumer appetite for beer, which has negatively impacted overall sales and the company's financial health.
- Increased Soft Drink Reliance: In response to declining beer sales, the company is increasingly relying on its soft drink offerings, a shift that may alleviate some pressure in the short term but could affect brand image and market positioning in the long run.
- Changing Market Demand: As consumer preferences shift towards healthier beverage options, the beer industry faces significant challenges, forcing the company to reassess its product portfolio to align with new market trends.
- Need for Strategic Adjustment: Given the earnings decline, the Danish brewer must develop new strategies to enhance its competitiveness in the soft drink market while also seeking effective ways to revive beer sales.
See More
Novo Nordisk Warns of Sales Decline Amid Price Pressures
- Sales Warning: Novo Nordisk released its earnings report early, projecting a decline in sales and profit growth this year primarily due to lower prices in the U.S. and the loss of exclusivity for its weight loss drugs Wegovy and Ozempic in China, Brazil, and Canada, which may dampen market confidence.
- Stock Reaction: Following the warning, Novo Nordisk's share price tumbled significantly, reflecting investor concerns about future performance, which could impact the company's competitiveness and investor confidence in global markets.
- Market Impact: European stocks are expected to open flat to higher, with the FTSE and DAX slightly up, and the CAC 40 rising by 0.24%, indicating a cautiously optimistic market sentiment ahead of upcoming earnings reports, despite overall sentiment being affected by a short-lived sell-off in cryptocurrencies and precious metals.
- Earnings Focus: On Wednesday, several companies including Novo Nordisk, Banco Santander, and GSK are set to report earnings, with the market closely monitoring these reports for their implications on overall economic and industry trends, especially amid increasing economic uncertainty.
See More
Trump Reaches Greenland Framework Agreement, European Stocks Rise
- Market Rebound: Following Trump's announcement of a framework agreement with NATO Secretary General, European stocks are expected to open higher, with the UK's FTSE up 0.8%, Germany's DAX up 1.3%, France's CAC 40 up 1.2%, and Italy's FTSE MIB up 1.5%, reflecting positive market sentiment amid easing trade tensions.
- Framework Agreement Details: During the World Economic Forum in Davos, Trump indicated that the framework would involve U.S.-European collaboration on a proposed Golden Dome missile defense system and access to mineral resources in Greenland, although he acknowledged that specific details are still to be clarified.
- Trade Agreement Uncertainty: Despite the framework agreement, European lawmakers have suspended the approval of last year's EU-U.S. trade deal, introducing uncertainty into future trade relations and potentially impacting market confidence.
- Global Economic Impact: Trump's address and the agreement may influence global economic trends, particularly regarding trade policies and international cooperation, likely prompting further discussions among business leaders and political figures at the World Economic Forum.
See More
